ZA200405246B - Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation. - Google Patents

Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation. Download PDF

Info

Publication number: ZA200405246B
Authority: ZA; South Africa
Prior art keywords: oxobutanoic acid; substance; composition; benzyl; chosen
Prior art date: 2001-12-03

Application number

ZA200405246A

Other languages

English (en)

Inventor

Gerard Moinet

Philippe Maizeray

Dominique Marais

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-03

Filing date

2004-07-01

Publication date

2005-06-24

2004-07-01 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2005-06-24 Publication of ZA200405246B publication Critical patent/ZA200405246B/en

Links

230000004054 inflammatory process Effects 0.000 title claims description 20
206010061218 Inflammation Diseases 0.000 title claims description 19
UIUJIQZEACWQSV-UHFFFAOYSA-N succinic semialdehyde Chemical class OC(=O)CCC=O UIUJIQZEACWQSV-UHFFFAOYSA-N 0.000 title claims description 14
239000000126 substance Substances 0.000 claims description 18
150000001875 compounds Chemical class 0.000 claims description 16
125000003118 aryl group Chemical group 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
150000003839 salts Chemical class 0.000 claims description 12
-1 cyano, hydroxyl Chemical group 0.000 claims description 11
239000012453 solvate Substances 0.000 claims description 10
125000000217 alkyl group Chemical group 0.000 claims description 9
230000007170 pathology Effects 0.000 claims description 9
239000002253 acid Substances 0.000 claims description 7
239000003814 drug Substances 0.000 claims description 7
125000004432 carbon atom Chemical group C* 0.000 claims description 6
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 6
HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 4
150000007513 acids Chemical class 0.000 claims description 4
206010012601 diabetes mellitus Diseases 0.000 claims description 4
125000002541 furyl group Chemical group 0.000 claims description 4
125000001072 heteroaryl group Chemical group 0.000 claims description 4
125000004076 pyridyl group Chemical group 0.000 claims description 4
125000000714 pyrimidinyl group Chemical group 0.000 claims description 4
125000000168 pyrrolyl group Chemical group 0.000 claims description 4
125000001424 substituent group Chemical group 0.000 claims description 4
125000001544 thienyl group Chemical group 0.000 claims description 4
201000001320 Atherosclerosis Diseases 0.000 claims description 3
208000008035 Back Pain Diseases 0.000 claims description 3
208000032131 Diabetic Neuropathies Diseases 0.000 claims description 3
206010020772 Hypertension Diseases 0.000 claims description 3
102000004877 Insulin Human genes 0.000 claims description 3
108090001061 Insulin Proteins 0.000 claims description 3
208000008930 Low Back Pain Diseases 0.000 claims description 3
206010054805 Macroangiopathy Diseases 0.000 claims description 3
208000001145 Metabolic Syndrome Diseases 0.000 claims description 3
208000002193 Pain Diseases 0.000 claims description 3
206010036030 Polyarthritis Diseases 0.000 claims description 3
208000017442 Retinal disease Diseases 0.000 claims description 3
206010038923 Retinopathy Diseases 0.000 claims description 3
201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 3
125000003545 alkoxy group Chemical group 0.000 claims description 3
206010003246 arthritis Diseases 0.000 claims description 3
229910052736 halogen Inorganic materials 0.000 claims description 3
150000002367 halogens Chemical class 0.000 claims description 3
229940125396 insulin Drugs 0.000 claims description 3
208000017169 kidney disease Diseases 0.000 claims description 3
206010062198 microangiopathy Diseases 0.000 claims description 3
230000004770 neurodegeneration Effects 0.000 claims description 3
208000015122 neurodegenerative disease Diseases 0.000 claims description 3
201000001119 neuropathy Diseases 0.000 claims description 3
230000007823 neuropathy Effects 0.000 claims description 3
201000008482 osteoarthritis Diseases 0.000 claims description 3
208000033808 peripheral neuropathy Diseases 0.000 claims description 3
208000030428 polyarticular arthritis Diseases 0.000 claims description 3
238000002636 symptomatic treatment Methods 0.000 claims description 3
125000003806 alkyl carbonyl amino group Chemical group 0.000 claims description 2
125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 2
125000004656 alkyl sulfonylamino group Chemical group 0.000 claims description 2
125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 2
125000000753 cycloalkyl group Chemical group 0.000 claims description 2
125000000623 heterocyclic group Chemical group 0.000 claims description 2
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
125000005936 piperidyl group Chemical group 0.000 claims description 2
125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 2
125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 2
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 2
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 2
206010030113 Oedema Diseases 0.000 description 10
230000003110 anti-inflammatory effect Effects 0.000 description 6
210000002683 foot Anatomy 0.000 description 5
241000700159 Rattus Species 0.000 description 4
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 4
239000000679 carrageenan Substances 0.000 description 3
229940113118 carrageenan Drugs 0.000 description 3
235000010418 carrageenan Nutrition 0.000 description 3
229920001525 carrageenan Polymers 0.000 description 3
210000000548 hind-foot Anatomy 0.000 description 3
238000002347 injection Methods 0.000 description 3
239000007924 injection Substances 0.000 description 3
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 3
DZRBTTWGDHUKDS-UHFFFAOYSA-N 2-benzyl-4-(4-fluorophenyl)-4-oxobutanoic acid Chemical compound C=1C=CC=CC=1CC(C(=O)O)CC(=O)C1=CC=C(F)C=C1 DZRBTTWGDHUKDS-UHFFFAOYSA-N 0.000 description 2
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
239000000017 hydrogel Substances 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
229960000905 indomethacin Drugs 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
239000000546 pharmaceutical excipient Substances 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
208000024827 Alzheimer disease Diseases 0.000 description 1
208000037260 Atherosclerotic Plaque Diseases 0.000 description 1
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
208000018737 Parkinson disease Diseases 0.000 description 1
125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
239000004411 aluminium Substances 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003472 antidiabetic agent Substances 0.000 description 1
229940125708 antidiabetic agent Drugs 0.000 description 1
229910052797 bismuth Inorganic materials 0.000 description 1
JCXGWMGPZLAOME-UHFFFAOYSA-N bismuth atom Chemical compound [Bi] JCXGWMGPZLAOME-UHFFFAOYSA-N 0.000 description 1
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
229910052794 bromium Inorganic materials 0.000 description 1
125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
230000000694 effects Effects 0.000 description 1
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
125000003983 fluorenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3CC12)* 0.000 description 1
229910052731 fluorine Inorganic materials 0.000 description 1
239000011737 fluorine Substances 0.000 description 1
239000000499 gel Substances 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229910052742 iron Inorganic materials 0.000 description 1
125000002510 isobutoxy group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])O* 0.000 description 1
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
159000000001 potassium salts Chemical class 0.000 description 1
239000000843 powder Substances 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000007940 sugar coated tablet Substances 0.000 description 1
239000003826 tablet Substances 0.000 description 1
125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
208000001072 type 2 diabetes mellitus Diseases 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Epidemiology (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Diabetes (AREA)
Neurology (AREA)
Physical Education & Sports Medicine (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Pain & Pain Management (AREA)
Immunology (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Urology & Nephrology (AREA)
Vascular Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Pulmonology (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ZA200405246A 2001-12-03 2004-07-01 Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation. ZA200405246B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0115601A FR2832925B1 (fr)	2001-12-03	2001-12-03	Utilisation de derives de l'acide 4-oxobutanoique dans le traitement de l'inflammation

Publications (1)

Publication Number	Publication Date
ZA200405246B true ZA200405246B (en)	2005-06-24

Family

ID=8870049

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200405246A ZA200405246B (en)	2001-12-03	2004-07-01	Use of 4-oxobutanoic acid derivatives in the treatnent of inflammation.

Country Status (19)

Country	Link
US (1)	US7897644B2 (fr)
EP (1)	EP1450780B1 (fr)
JP (1)	JP2005511654A (fr)
KR (1)	KR20050043728A (fr)
CN (1)	CN1599604A (fr)
AT (1)	ATE355834T1 (fr)
AU (1)	AU2002342883B2 (fr)
BR (1)	BR0214644A (fr)
CA (1)	CA2468910C (fr)
DE (1)	DE60218726T2 (fr)
ES (1)	ES2280589T3 (fr)
FR (1)	FR2832925B1 (fr)
HU (1)	HUP0402242A3 (fr)
MX (1)	MXPA04005265A (fr)
PL (1)	PL369845A1 (fr)
RU (1)	RU2004120557A (fr)
TW (1)	TW200300670A (fr)
WO (1)	WO2003047561A1 (fr)
ZA (1)	ZA200405246B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2008333635A1 (en) *	2007-12-03	2009-06-11	Merck Patent Gmbh	Use of 4-oxobutanoic acid derivatives in the treatment of pathologies associated with immunological disorders

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3784701A (en) *	1970-09-21	1974-01-08	American Cyanamid Co	Compositions containing substituted benzoylpropionic acids and method of use to treat inflammation and pain
JPS59144717A (ja) *	1983-02-07	1984-08-18	Microbial Chem Res Found	鎮痛剤
US5789434A (en) *	1994-11-15	1998-08-04	Bayer Corporation	Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
GB9522615D0 (en) *	1995-11-03	1996-01-03	Pharmacia Spa	4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity
HRP970247B1 (en) *	1996-05-15	2002-02-28	Bayer Ag	Substituted 4-arylbutric acid derivatives as matrix metalloprotease inhibitors
FR2752422B1 (fr) *	1996-08-16	1998-11-06	Lipha	Composition pharmaceutique contenant des acides 4-oxo-butanoiques
FR2777566B1 (fr) *	1998-04-15	2003-02-21	Synthelabo	Derives d'azacycloalcanes, leur preparation et leur application en therapeutique
US6060250A (en) *	1998-06-30	2000-05-09	Incyte Pharmaceuticals, Inc.	Human transferases
WO2000006560A1 (fr) *	1998-07-30	2000-02-10	Warner-Lambert Company	Composes heteroaromatiques tricycliques et leurs derives utilises comme inhibiteurs des metalloproteinases matricielles
FR2793411B1 (fr) *	1999-05-11	2001-06-29	Synthelabo	Utilisation de derives de l'acide succinique pour obtenir un medicament destine au traitement de l'inflammation
US20030040490A1 (en) *	2000-02-24	2003-02-27	Yasuo Sugiyama	Drugs containing combined active ingredients

2001
- 2001-12-03 FR FR0115601A patent/FR2832925B1/fr not_active Expired - Fee Related
2002
- 2002-11-06 DE DE60218726T patent/DE60218726T2/de not_active Expired - Lifetime
- 2002-11-06 KR KR1020047006346A patent/KR20050043728A/ko not_active Withdrawn
- 2002-11-06 MX MXPA04005265A patent/MXPA04005265A/es unknown
- 2002-11-06 RU RU2004120557/15A patent/RU2004120557A/ru not_active Application Discontinuation
- 2002-11-06 AT AT02779532T patent/ATE355834T1/de not_active IP Right Cessation
- 2002-11-06 JP JP2003548817A patent/JP2005511654A/ja not_active Ceased
- 2002-11-06 US US10/497,491 patent/US7897644B2/en not_active Expired - Fee Related
- 2002-11-06 WO PCT/EP2002/012357 patent/WO2003047561A1/fr not_active Ceased
- 2002-11-06 AU AU2002342883A patent/AU2002342883B2/en not_active Ceased
- 2002-11-06 HU HU0402242A patent/HUP0402242A3/hu unknown
- 2002-11-06 CA CA2468910A patent/CA2468910C/fr not_active Expired - Fee Related
- 2002-11-06 CN CNA028241045A patent/CN1599604A/zh active Pending
- 2002-11-06 ES ES02779532T patent/ES2280589T3/es not_active Expired - Lifetime
- 2002-11-06 BR BR0214644-4A patent/BR0214644A/pt not_active IP Right Cessation
- 2002-11-06 EP EP02779532A patent/EP1450780B1/fr not_active Expired - Lifetime
- 2002-11-06 PL PL02369845A patent/PL369845A1/xx unknown
- 2002-11-29 TW TW091134839A patent/TW200300670A/zh unknown
2004
- 2004-07-01 ZA ZA200405246A patent/ZA200405246B/en unknown

Also Published As

Publication number	Publication date
WO2003047561A1 (fr)	2003-06-12
EP1450780A1 (fr)	2004-09-01
AU2002342883B2 (en)	2007-11-29
CA2468910A1 (fr)	2003-06-12
AU2002342883A1 (en)	2003-06-17
CA2468910C (fr)	2012-01-03
MXPA04005265A (es)	2004-10-11
US7897644B2 (en)	2011-03-01
KR20050043728A (ko)	2005-05-11
ATE355834T1 (de)	2007-03-15
EP1450780B1 (fr)	2007-03-07
CN1599604A (zh)	2005-03-23
JP2005511654A (ja)	2005-04-28
DE60218726T2 (de)	2007-11-15
HUP0402242A3 (en)	2006-01-30
DE60218726D1 (de)	2007-04-19
PL369845A1 (en)	2005-05-02
ES2280589T3 (es)	2007-09-16
US20050014768A1 (en)	2005-01-20
FR2832925B1 (fr)	2006-07-14
RU2004120557A (ru)	2005-05-10
TW200300670A (en)	2003-06-16
HUP0402242A2 (hu)	2005-02-28
FR2832925A1 (fr)	2003-06-06
BR0214644A (pt)	2004-11-03

Publication	Publication Date	Title
KR100264814B1 (ko)	2000-09-01	광학적으로 순수한 r-케토로락을 포함하는 조성물과 무통 및 해열치료에 이를 사용하는 방법
DE69532216D1 (de)	2004-01-08	1-Acetyl-5-Bromo-4,6-Dimethylindolin
RU2007148994A (ru)	2009-07-10	Композиции и способы лечения заболевания сетчатки
JPH01224316A (ja)	1989-09-07	医薬製剤
KR20090129994A (ko)	2009-12-17	고지혈증 예방 및/또는 치료제
RS49504B (sr)	2006-10-27	Antitrombični i antiaterogeni farmaceutski preparat koji obuhvata derivat tienopiridina i inhibitor hmg-coa-reduktaze
CN103796662A (zh)	2014-05-14	包含鳄梨/大豆不皂化物和类脂酸的口服施用组合物及施用方法
AU2005237543B2 (en)	2011-02-10	Statins for the treatment of ocular hypertension and glaucoma
CA2468910C (fr)	2012-01-03	Utilisation de derives de l'acide 4-oxobutanoique pour le traitement d'inflammations
RU2006104024A (ru)	2006-07-27	Каппа-агонисты, в особенности для лечения и/или профилактики синдрома раздраженной толстой кишки
JP3112944B2 (ja)	2000-11-27	（ｒ）−２−（３−ベンゾイルフェニル）プロピオン酸を含有する鎮痛剤として有用な薬学的組成物
JPH06500537A (ja)	1994-01-20	アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用
WO2003045368A1 (fr)	2003-06-05	Composition pharmaceutique contenant une combinaison de metformine et d'un acide 4-oxobutanoique et son utilisation pour traiter le diabete
JP3094077B2 (ja)	2000-10-03	５−（２−クロロ−１−ヒドロキシエチル）−４−メチルチアゾール含有の医薬製剤
AU2016381152A1 (en)	2018-07-26	Indolizine derivatives, composition and methods of use
EP0579222A2 (fr)	1994-01-19	Composition améliorant le métabolisme lipidique
HK1070837A (en)	2005-06-30	Use of 4-oxobutanoic acid derivatives in the treatment of inflammation
KR20040075871A (ko)	2004-08-30	알파-글루코시다제 저해제 및 ４-옥소부탄산을 포함하여이루어지는 약제학적 조성물 및 당뇨병을 치료하기 위한이의 용도
AU2572400A (en)	2000-09-04	Intermittent claudication therapeutic drugs comprising pyrroloazepines
WO2003047574A1 (fr)	2003-06-12	Composition pharmaceutique renfermant un derive de type 5-phenoxyalkyl-2,4-thiazolidinedione et un acide 4-oxobutanoique
EP1463503A1 (fr)	2004-10-06	Composition pharmaceutique contenant une glitazone et un acide 4-oxobutanoique, et utilisation de cette composition dans le traitement du diabete